Actiste: a complete diabetes-care solution designed for telemedicine, introducing new possibilities in healthcare.
Actiste is the world's first complete IoT care solution for assisting and treating insulin-dependent diabetes. The unit brings together and combines all the necessary functions for diabetes care – blood sampling, blood glucose measurement and drug injection – in a single connected device. Brighter is the only company in the market offering an all-in-one device, presenting a unique opportunity for improved health outcomes and efficiency in healthcare.
The Actiste device is offered as part of a subscription service at par with the monthly average cost of a blood glucose monitor, injection pen and related consumables for type 1 and type 2 diabetes patients in the market. The service includes a digital platform for everyday support, feedback and management, global connectivity, different levels of data sharing, continuous replenishment of consumables directly to the home, and enables personalized coaching to continuously optimize and improve treatments.
The device is based on patented technology for collecting data on specified biomarkers and injected volumes of drugs. With state-of-the-art eSIM technology provided by Ericsson, Actiste has global out-of-the-box connectivity, making it completely independent of other devices to utilize and share health and treatment data. The “always connected” mentality, ensuring that all relevant health/medical data is secured no matter where you are, is crucial to be successful in diabetes management – a highly data-driven disease.
The concept of which the Actiste Service is based upon is something we call The Benefit Loop – the heart of Brighter, a self-improving treatment loop, driven by increased access to data, real-world analysis, healthcare access, and most importantly, personalized feedback to drive effective motivation and help the individual stay on track and follow treatment recommendations. To add even more value, Brighter has also launched a unique digital community for young people living with diabetes – a safe space to discuss, learn and connect.
Actiste is built upon a unique, patented platform with two CE marks (Actiste is regulated under both the EU Medical Devices Directive (MDD) and Vitro Diagnostic Devices Directive (IVDD) due to the multiple functions of the device), AI monitoring of a medical device, log of actually injected drug, future proof with a global license for micro needle technology for biomarker measurement and injection for application to diabetes.
By providing time stamped, correlated, valid, real-life data on blood-glucose values and actually injected insulin volume, Actiste gives people with diabetes and their caregivers a clearer picture of the condition and closer control over daily care. This can support improved adherence to treatment guidelines, peace of mind for family members, and more efficient use of limited healthcare resources.
The Actiste Service has several additional applications beyond the ability to remotely monitor diabetes patients’ health. The clinical patient data that Actiste provides can be used for descriptive statistics and demographic analysis with selections of data, down to the individual level.
To address a wider group of patients suffering from diabetes, Brighter recently expanded the Actiste family with Actiste Mini, based on the same technological platform as Actiste but without the insulin injection functionality. This means Brighter can support the whole global diabetes community going forward.